January 2, 2014 — Fujifilm Medical Systems U.S.A. Inc., offered the latest version of Synapse RIS (radiology information system), a complete electronic health record (EHR)-certified solution that can be adapted to meet Meaningful Use (MU) Stage II requirements for radiology professionals at the Radiological Society of North America Annual Meeting (RSNA 2013) in Chicago.
“Synapse RIS has integrated EHR into a powerful radiology management tool that can enhance workflow and increase the productivity of radiology practices,” said Jim Morgan, vice president of medical informatics, Fujifilm. “The platform offers the flexibility needed to support additional stages of meaningful use criteria, as well as other government regulations that may be forthcoming.”
Synapse RIS integrates with Synapse PACS (picture archiving and communication system) and has additional productivity enhancing features for radiologists such as:
- An interactive analytics dashboard that provides a visual snapshot of key performance indicators
- Peer review capabilities directly integrated into the diagnostic process
- Urgent findings for providing closed-loop communications and compliance
- Patient portal capabilities to empower patients, reduce wait times and satisfy meaningful use criteria
Integration with ACR Select allows practices to obtain guidance as to the most appropriate imaging procedure at computerized physician order entry (CPOE) and at point of schedule. This ensures patients get the proper imaging procedure, and the order is based on a structured reason for exam.
The Meaningful Use initiative provides incentive payments to eligible professionals (EPs) who use a certified, complete EHR solution in a meaningful way. The American College of Radiologists (ACR) has projected that 90 percent of radiologists can qualify for EHR. In the Stage 1 meaningful use regulations, CMS had established a timeline that required providers to progress to Stage 2 criteria after two years under the Stage 1 criteria. This timeline would require Medicare providers who first demonstrated meaningful use in 2011 to meet the Stage 2 criteria in 2014.
For more information: www.fujimed.com, rsna.fujimed.com
March 10, 2026 
